In the email sent by Li Changhua to Su Zhe, he listed a number of pharmaceutical companies.

Although these are all pharmaceutical companies that can be transferred intentionally, there are few pharmaceutical companies that can meet Su Zhe's conditions when they are really screened.

Among them, the smallest pharmaceutical company is almost as large as the Changhua Pharmaceutical Factory, and its productivity is slightly smaller than that of the Changhua Pharmaceutical Factory.

The pharmaceutical company, covering an area of 4.8 hectares in Shenzhou High-tech Zone, includes the construction of solid preparation plants, raw materials and finished product warehouses and company office buildings, with a total construction area of 21,000 square meters and an annual output of 1.8 billion capsules, 400 million bags of granules and 900 million tablets.

If it is acquired, after integration, it can double the output of Changhua Pharmaceutical Factory.

However, Su Zhe was directly eliminated, and the output could only be doubled, which was of little significance to Changhua Pharmaceutical Factory.

Although it is now necessary to solve it at one time, it is impossible for Changhua Pharmaceutical to solve the output problem once and for all.

However, Su Zhe's condition, at least after acquiring the pharmaceutical company, can no longer worry about the productivity of Changhua Pharmaceutical in a short period of time.

And such a large and small pharmaceutical company, there is no need to consider it, I believe that even after the acquisition, according to the current development speed of Changhua Pharmaceutical, such productivity will soon reach its peak.

It also takes time for Changhua Pharmaceutical to integrate and acquire pharmaceutical companies, and Su Zhe doesn't want to waste time on this.

So Su Zhe would not consider a pharmaceutical company of this size at all.

Of course, the purchase price of this pharmaceutical company with low output is also relatively low. And like this pharmaceutical company. The estimated purchase price is $320 million.

Except for this one pharmaceutical company. There are also several pharmaceutical companies, all of which are not large, and the estimated purchase price is between 300 million and 800 million.

But these pharmaceutical companies were not in Su Zhe's consideration, so he skipped these pharmaceutical companies first.

The estimated purchase price of the next few pharmaceutical companies is more than 1 billion.

A pharmaceutical company of this size. is what Su Zhe wants. Therefore, Su Zhe directly started to choose from here.

In the end, after Su Zhe carefully checked the information, one of them was called Xinjing Pharmaceutical Company, which made him the most satisfied.

However, the size of this pharmaceutical company is the largest among them, and its purchase price is also the highest.

This Xinjing pharmaceutical company has not been established for a long time, and the founder of this Xinjing pharmaceutical company at that time was ambitious. I want to create a first-class pharmaceutical company.

Therefore, when Xinjing Pharmaceutical Company built a factory, the investment was huge. The introduced production line is also regarded as an international advanced level and a first-class modern production line in China, with more than 1,000 employees.

The Xinjing pharmaceutical company mainly produces eight categories of preparations, including tablets, capsules, granules, water injections, powder injections, lyophilized powder injections, oral liquids, and soft capsules, as well as eight categories of raw materials, including erythromycin, erythromycin, tetracycline hydrochloride, erythromycin, calcium oxybenzenesulfonate, urapidil, isoVC sodium, and leucon.

This Xinjing pharmaceutical enterprise covers an area of 440,000 square meters, with a construction area of 180,000 square meters, and its output is several times that of Changhua Pharmaceutical.

It can produce 12 billion tablets, 8 billion capsules, 140 million granules, 50 million water injections, 20 million powder injections, and 20 million lyophilized powder injections per year.

However, it is a pity that this Xinjing pharmaceutical company, since its establishment, has been lacking its own flagship products, and its own products have not been well-known and cannot open the drug market.

As a result, the Xinjing pharmaceutical company has been unable to make ends meet.

In order to maintain its operation, Xinjing pharmaceutical companies are mainly OEM, and the output of independent products is very low.

The situation of this Xinjing pharmaceutical company is almost the same as before Changhua Pharmaceutical was not invested by Su Zhe, they are all heavily indebted and facing bankruptcy or acquisition.

The difference is that the scale of this Xinjing pharmaceutical company is much larger than that of Changhua Pharmaceutical, and the debt is also higher.

Now it is preliminarily estimated that Changhua Pharmaceutical will need to pay a huge amount of money to acquire Xinjing Pharmaceutical Company.

In fact, Li Changhua and Liu Xiong's choices are the same as Su Zhe's, and among the pharmaceutical companies listed by the two of them, there are three that have been specially annotated and asked Su Zhe to consider carefully.

And Su Zhe is now looking at Xinjing Pharmaceutical Company, which is one of them, and they are also optimistic about Xinjing Pharmaceutical Company.

What makes Su Zhe and his heart the most exciting is that Xinjing Pharmaceutical Company also has 50,000 acres of land and a Chinese herbal medicine planting base, which is one of the reasons why they fancy this pharmaceutical company.

Because of this Chinese herbal medicine planting base, most of the Chinese medicinal materials planted are needed for the production of drugs such as thawing spirit.

Therefore, if Changhua Pharmaceutical acquires Xinjing Pharmaceutical Company and owns the 50,000 acres of Chinese herbal medicine planting base, then Changhua Pharmaceutical will not have to worry about being curbed in the production of raw materials.

Previously, Liu Xiong proposed to build his own Chinese herbal medicine planting base, because he was mainly worried that Changhua Pharmaceutical would be controlled by other sources in the raw materials.

If Changhua Pharmaceutical has its own Chinese herbal medicine planting base, there is no need to worry about this trouble.

Now I didn't expect that Xinjing Pharmaceutical Company also has its own Chinese herbal medicine planting base, and its scale has reached 50,000 acres.

It can be seen that at that time, Xinjing Pharmaceutical Company had the determination to develop into a first-class pharmaceutical company, otherwise it would not have created the entire production chain.

It's just that Xinjing Pharmaceutical Company has had bad luck and has not been able to develop favorable products, coupled with a business trip in management, so it will face this situation.

With this kind of condition, Xinjing Pharmaceutical Company will become the best choice for Su Zhe and them.

Su Zhe thought that Li Changhua and Liu Xiong should be the same as him, and it was because of this that he took a fancy to Xinjing Pharmaceutical Company.

However, it is not easy to acquire Xinjing Pharmaceutical Company.

Although Xinjing Pharmaceutical Company now has the intention of transferring, its selling price is not low.

With the current scale of Xinjing Pharmaceutical Company, as well as the fact that it has a Chinese herbal medicine planting base, and includes taking on debts, etc., the preliminary valuation of Changhua Pharmaceutical needs to pay 2.2 billion yuan for this.

Although the sales of the three drugs launched by Changhua Pharmaceutical Factory are very good, after all, the launch time of these three drugs is only a few months at most.

And because the price of drugs such as thawing is too low, the profit is actually not high, and the sales time is not long.

Therefore, the funds accumulated by Changhua Pharmaceutical Factory are actually not very sufficient. (To be continued......)